fingolimod has been researched along with fty 720p in 19 studies
| Studies (fingolimod) | Trials (fingolimod) | Recent Studies (post-2010) (fingolimod) | Studies (fty 720p) | Trials (fty 720p) | Recent Studies (post-2010) (fty 720p) |
|---|---|---|---|---|---|
| 65 | 0 | 51 | 25 | 0 | 12 |
| 65 | 0 | 51 | 21 | 0 | 16 |
| Protein | Taxonomy | fingolimod (IC50) | fty 720p (IC50) |
|---|---|---|---|
| Sphingosine 1-phosphate receptor 2 | Homo sapiens (human) | 0.5504 | |
| Sphingosine 1-phosphate receptor 4 | Homo sapiens (human) | 0.015 | |
| Sphingosine 1-phosphate receptor 1 | Homo sapiens (human) | 0.0008 | |
| Sodium-dependent serotonin transporter | Homo sapiens (human) | 0.015 | |
| Sphingosine 1-phosphate receptor 3 | Homo sapiens (human) | 0.0147 | |
| Sphingosine 1-phosphate receptor 5 | Homo sapiens (human) | 0.0008 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.79) | 29.6817 |
| 2010's | 14 (73.68) | 24.3611 |
| 2020's | 2 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Ann Keohane, C; Bergstrom, J; Card, D; Chrebet, G; Hajdu, R; Hale, JJ; Jackson, JJ; Koo, GC; Koprak, SL; Mandala, S; Milligan, J; Mills, SG; Neway, W; Rosen, H; Rosenbach, M; Shei, GJ | 1 |
| Bergstrom, J; Card, D; Chrebet, G; Ferrer, M; Hajdu, R; Hale, JJ; Hodder, P; Keohane, CA; Lynch, CL; Mandala, S; Milligan, JA; Mills, SG; Neway, W; Parent, SA; Rosen, H; Rosenbach, MJ; Shei, GJ; Strulovici, B | 1 |
| Albert, R; Brinkmann, V; Cooke, N; Francotte, E; Guerini, D; Hinterding, K; Knecht, H; Müller-Hartwieg, C; Simeon, C; Streiff, M; Wagner, T; Welzenbach, K; Zécri, F; Zollinger, M | 1 |
| Adachi, K; Asayama, M; Hamada, M; Kiuchi, M; Marukawa, K; Nakamura, M; Sato, N; Shimano, K; Sugahara, K; Takagi, K; Tomatsu, A | 1 |
| Bernier, SG; Deng, H; Doyle, E; Evindar, G; Lorusso, J; Morgan, BA; Westlin, WF | 1 |
| Chen, X; Hu, J; Jin, J; Tian, Y; Wang, X; Xiao, Q; Yin, D; Zhou, W | 1 |
| Balimane, P; Barrish, JC; Carter, PH; Cornelius, G; Cvijic, ME; D'Arienzo, CJ; Dabros, M; Dhar, TG; Dyckman, AJ; Heimrich, EM; Hennan, J; Lehman-McKeeman, LD; Levesque, PC; Marino, AM; Mathur, A; McIntyre, KW; Salter-Cid, L; Shen, DR; Shi, H; Taylor, TL; Thomas, R; Warrack, B; Wu, DR; Xiao, HY; Xie, J; Yang, X; Yang, Z; Zhou, XD; Zhu, JL | 1 |
| Edinger, AL; Garsi, JB; Hanessian, S; McCracken, AN; Sernissi, L; Simitian, G; Vece, V | 1 |
| Carter, PH; Cornelius, G; Cvijic, ME; Dhar, TGM; Dyckman, AJ; Gilmore, JL; Lehman-McKeeman, LD; Levesque, PC; Marino, AM; Mathur, A; McIntyre, KW; Pang, J; Salter-Cid, L; Shen, DR; Shi, H; Sun, H; Taylor, TL; Warrack, BM; Xiao, HY; Xiao, Z; Xie, J; Yang, M; Yang, X | 1 |
| Bahn, YS; Cheong, E; Choi, JW; Hwang, H; Kim, B; Kim, HJ; Kim, J; Kim, JW; Kim, R; Kim, S; Kim, Y; Lee, EH; Lee, HY; Lee, J; Park, JH; Park, KD; Park, SJ; Seo, SH; Yeon, SK | 1 |
| Black, C; Chollate, S; Guckian, KM; Hahm, K; Hetu, G; Jin, P; Kumaravel, G; Lee, WC; Lin, EY; Luo, Y; Lynch, KR; Ma, B; Macdonald, TL; Rohde, E; Rossomando, A; Scannevin, R; Scott, D; Wang, J; Yang, C | 1 |
| Oberlies, NH; Pearce, CJ; Strader, CR | 1 |
| Arnett, HA; Cee, VJ; Croghan, MD; Fiorino, M; Fotsch, C; Frohn, MJ; Harrington, PE; Horner, M; Lanman, BA; Lee, MR; McElvain, M; Morrison, HG; Pennington, LD; Pickrell, AJ; Reed, AB; Sham, KK; Tasker, AS; Wong, M; Xu, H; Xu, Y; Zhang, X | 1 |
| Fukuda, T; Goto, T; Honda, T; Ikeda, T; Inaba, S; Izumi, T; Kagari, T; Kawase, Y; Kimura, T; Mizuno, Y; Nakamura, T; Nara, F; Nishi, T; Sekiguchi, Y; Shimozato, T; Suzuki, K; Takemoto, T; Tamura, M; Tsuji, T; Yahara, C | 1 |
| Al-Shamma, H; Anthony, T; Barden, J; Behan, DP; Blackburn, A; Buzard, DJ; Calderon, I; Calvano, L; Chen, C; Chen, W; Christopher, RJ; Edwards, J; Fu, L; Gaidarov, I; Gao, Y; Gatlin, J; Gharbaoui, T; Han, S; Jones, RM; Kawasaki, A; Kim, SH; Le, M; Lehmann, J; Lopez, L; Ma, YA; Mills, D; Montalban, AG; Moody, J; Morgan, M; Rueter, J; Sadeque, A; Sage, C; Semple, G; Sengupta, D; Solomon, M; Stirn, S; Thatte, J; Thoresen, L; Ullman, B; Unett, DJ; Usmani, K; Whelan, K; Zhu, X | 1 |
| Bannen, LC; Betageri, R; Chan, DS; DiSalvo, D; Fletcher, K; Harcken, C; Hickey, E; Hill-Drzewi, M; Hopkins, TD; Horan, JC; Kemper, RA; Kuzmich, D; Lemieux, RM; Levin, JI; Linehan, B; Liu, P; Lord, J; Mac, MB; Mao, C; Miller, C; Modis, LK; Ng, S; Patel, M; Patenaude, L; Smith, D; Studwell, D; Terenzzio, D; Wang, Y; Xia, H; Xu, W; Yu, H | 1 |
| Bailey, JM; Bit, RA; Brown, JA; Campbell, CA; Deeks, N; Demont, EH; Dowell, SJ; Eldred, C; Gaskin, P; Gray, JR; Haynes, A; Hirst, DJ; Holmes, DS; Kumar, U; Morse, MA; Osborne, GJ; Renaux, JF; Seal, GA; Smethurst, CA; Taylor, S; Watson, R; Willis, R; Witherington, J | 1 |
| Balimane, P; Banas, D; Barrish, JC; Carter, PH; Cornelius, G; Cvijic, ME; D'Arienzo, C; Dyckman, AJ; Gillooly, K; Guo, J; Langevine, CM; Liu, R; Marino, A; McIntyre, KW; McKinnon, M; Moquin, RV; Pitts, WJ; Rex-Rabe, S; Salter-Cid, L; Shen, DR; Shuster, DJ; Spergel, SH; Suchard, SJ; Taylor, T; Warrack, B; Watterson, SH; Xie, J; Yarde, M | 1 |
| Borowski, V; Carter, PH; Chen, C; Cornelius, G; Cvijic, ME; D'Arienzo, CJ; Dabros, M; Dhar, TGM; Dyckman, AJ; Gilmore, JL; Gong, L; Gupta, A; Heimrich, EM; Lecureux, L; Lehman-McKeeman, LD; Levesque, PC; Li, Y; Marino, AM; Mathur, A; McIntyre, KW; Pragalathan, B; Rampulla, R; Salter-Cid, LM; Shen, DR; Shi, H; Sun, H; Taylor, TL; Thomas, R; Warrack, BM; Wu, DR; Xiao, HY; Xiao, Z; Xie, J; Yang, MG; Yang, X; Yang, Z; Zhou, XD | 1 |
1 review(s) available for fingolimod and fty 720p
| Article | Year |
|---|---|
Fingolimod (FTY720): a recently approved multiple sclerosis drug based on a fungal secondary metabolite.
Topics: Fatty Acids, Monounsaturated; Fingolimod Hydrochloride; Hypocreales; Immunosuppressive Agents; Multiple Sclerosis; Propylene Glycols; Sphingosine; Structure-Activity Relationship; United States; United States Food and Drug Administration | 2011 |
18 other study(ies) available for fingolimod and fty 720p
| Article | Year |
|---|---|
Potent S1P receptor agonists replicate the pharmacologic actions of the novel immune modulator FTY720.
Topics: Animals; CHO Cells; Cricetinae; Fingolimod Hydrochloride; Humans; Immunologic Factors; Immunosuppressive Agents; Injections, Intravenous; Male; Mice; Propylene Glycols; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine | 2004 |
A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists.
Topics: Administration, Oral; Animals; Azetidines; Biological Availability; CHO Cells; Cricetinae; Dogs; Drug Design; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Immunosuppressive Agents; Lymphocytes; Macaca mulatta; Mice; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2004 |
Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the biologically active species and its enantiomer.
Topics: Adjuvants, Immunologic; Animals; CHO Cells; Chromatography, High Pressure Liquid; Cricetinae; Cricetulus; Crystallography, X-Ray; Fingolimod Hydrochloride; Humans; Male; Organophosphates; Phosphorylation; Propylene Glycols; Radioligand Assay; Rats; Rats, Wistar; Receptors, Lysosphingolipid; Sphingosine; Stereoisomerism; Structure-Activity Relationship | 2005 |
Removal of sphingosine 1-phosphate receptor-3 (S1P(3)) agonism is essential, but inadequate to obtain immunomodulating 2-aminopropane-1,3-diol S1P(1) agonists with reduced effect on heart rate.
Topics: Animals; Biphenyl Compounds; Cell Line; Cricetinae; Cricetulus; Heart Rate; Immunologic Factors; Lymphocyte Count; Male; Mice; Mice, Inbred BALB C; Propanolamines; Propylene Glycols; Rats; Rats, Inbred F344; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2010 |
Discovery of Clinical Candidate GSK1842799 As a Selective S1P1 Receptor Agonist (Prodrug) for Multiple Sclerosis.
Topics: | 2013 |
Discovery of oxazole and triazole derivatives as potent and selective S1P(1) agonists through pharmacophore-guided design.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Drug Design; Heart Rate; Lymphocytes; Male; Models, Molecular; Molecular Conformation; Oxazoles; Rats; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Structure-Activity Relationship; Triazoles | 2014 |
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical Trials.
Topics: | 2016 |
In search of constrained FTY720 and phytosphingosine analogs as dual acting anticancer agents targeting metabolic and epigenetic pathways.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Epigenesis, Genetic; Fingolimod Hydrochloride; Mice; Molecular Structure; Sphingosine; Structure-Activity Relationship | 2018 |
Bicyclic Ligand-Biased Agonists of S1P
Topics: Animals; Arthritis, Experimental; Autoimmune Diseases; Biotransformation; Bridged Bicyclo Compounds; Bronchoalveolar Lavage Fluid; Chemotaxis, Leukocyte; Drug Evaluation, Preclinical; Half-Life; Humans; Lung Diseases; Male; Myocytes, Cardiac; Phosphorylation; Proprotein Convertases; Rats; Rats, Inbred Lew; Serine Endopeptidases; Structure-Activity Relationship | 2021 |
Discovery of Novel Sphingosine-1-Phosphate-1 Receptor Agonists for the Treatment of Multiple Sclerosis.
Topics: Animals; beta-Arrestins; Dogs; Drug Design; Encephalomyelitis, Autoimmune, Experimental; Heart Rate; Humans; Isoxazoles; Lymphocyte Count; Lymphocytes; Male; Mice; Multiple Sclerosis; Rats; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship; Triazoles | 2022 |
Stereochemistry-activity relationship of orally active tetralin S1P agonist prodrugs.
Topics: Administration, Oral; Animals; Crystallography, X-Ray; Immunosuppressive Agents; Lymphopenia; Mice; Models, Molecular; Multiple Sclerosis; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Prodrugs; Receptors, Lysosphingolipid; Structure-Activity Relationship; Tetrahydronaphthalenes | 2010 |
Quinolinone-based agonists of S1P₁: use of a N-scan SAR strategy to optimize in vitro and in vivo activity.
Topics: Animals; Area Under Curve; Cardiovascular Diseases; Chemistry, Physical; Drug Design; Female; Humans; Immunosuppressive Agents; In Vitro Techniques; Kinetics; Lymphocytes; Models, Chemical; Multiple Sclerosis; Quinolones; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship | 2012 |
Synthesis and SAR studies of benzyl ether derivatives as potent orally active S1P₁ agonists.
Topics: Administration, Oral; Animals; Binding Sites; Ethers; Graft Rejection; Half-Life; Heart Rate; Immunosuppressive Agents; Male; Molecular Docking Simulation; Protein Structure, Tertiary; Rats; Rats, Inbred Lew; Receptors, Lysosphingolipid; Structure-Activity Relationship; Transplantation, Homologous | 2014 |
Discovery of APD334: Design of a Clinical Stage Functional Antagonist of the Sphingosine-1-phosphate-1 Receptor.
Topics: | 2014 |
Late-stage optimization of a tercyclic class of S1P3-sparing, S1P1 receptor agonists.
Topics: Animals; Brain; Glutamic Acid; Hep G2 Cells; Humans; Hydrogen Bonding; Kinetics; Oxadiazoles; Rats; Receptors, Lysosphingolipid; Solubility; Structure-Activity Relationship; Thiadiazoles | 2016 |
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
Topics: Administration, Oral; Animals; Cell Line; Dogs; Dose-Response Relationship, Drug; Drug Discovery; Humans; Male; Mice; Mice, Inbred Strains; Molecular Structure; Pyrazoles; Pyridines; Rats; Rats, Inbred Lew; Rats, Sprague-Dawley; Receptors, Lysosphingolipid; Sphingosine-1-Phosphate Receptors; Structure-Activity Relationship | 2016 |
Potent and Selective Agonists of Sphingosine 1-Phosphate 1 (S1P1): Discovery and SAR of a Novel Isoxazole Based Series.
Topics: Animals; Arthritis, Experimental; Cell Movement; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Discovery; Encephalomyelitis, Autoimmune, Experimental; Humans; Immunosuppressive Agents; Isoxazoles; Lymphatic System; Lymphocytes; Lysophospholipids; Mice; Mice, Inbred C57BL; Rats; Rats, Inbred Lew; Sphingosine; Structure-Activity Relationship; Thymus Gland | 2016 |
Identification and Preclinical Pharmacology of ((1 R,3 S)-1-Amino-3-(( S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P
Topics: Animals; Bronchoalveolar Lavage Fluid; Clinical Trials as Topic; Dose-Response Relationship, Drug; Half-Life; Humans; Naphthalenes; Rats; Rats, Inbred Lew; Sphingosine-1-Phosphate Receptors; Tetrahydronaphthalenes | 2019 |